Glossary – I
This glossary provides brief explanations of terms used in the Ontario Public Drug Programs web pages. To access a term definition, select the appropriate letter from the alphabet below.
| ICR |
See Exceptional Access |
| Incremental cost-effectiveness ratio (ICER) |
The ratio of the difference between the cost of two alternatives and their effectiveness. |
| Indication |
In medicine, a sign, symptom, or medical condition that leads to the recommendation of a treatment, test, or procedure. |
| Induction therapy |
Treatment designed as a first step toward shrinking cancer and evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains. |
| Interchangeable |
The Executive Officer has the authority to designate a product as interchangeable with one or more other products when it is in the public interest to do so, and when it meets requirements and conditions set out in legislation. Legislation defines an interchangeable product as a drug or combination of drugs in a particular dosage and strength identified by a specific product name or manufacturer and designated as interchangeable with one or more such products. |
| Internal criteria |
Criteria the Committee to Evaluate Drugs (CED) developed to facilitate speedy internal screening and review of Individual Clinical Review (ICR)/Exceptional Access requests by pharmacists in the ministry’s Individual Eligibility and Review Branch (IERB). If requests do not meet the CED’s internal criteria, they are sent “externally” to a CED expert consultant for review. |
|
Text Only Version
